IL138488A0 - Polypeptides homologous to vegf and bmp1 - Google Patents

Polypeptides homologous to vegf and bmp1

Info

Publication number
IL138488A0
IL138488A0 IL13848899A IL13848899A IL138488A0 IL 138488 A0 IL138488 A0 IL 138488A0 IL 13848899 A IL13848899 A IL 13848899A IL 13848899 A IL13848899 A IL 13848899A IL 138488 A0 IL138488 A0 IL 138488A0
Authority
IL
Israel
Prior art keywords
vegf
bmp1
growth factor
polypeptides homologous
vascular endothelial
Prior art date
Application number
IL13848899A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/040,220 external-priority patent/US6391311B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL138488A0 publication Critical patent/IL138488A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
IL13848899A 1998-03-17 1999-03-10 Polypeptides homologous to vegf and bmp1 IL138488A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/040,220 US6391311B1 (en) 1998-03-17 1998-03-17 Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US18421698A 1998-11-02 1998-11-02
PCT/US1999/005190 WO1999047677A2 (fr) 1998-03-17 1999-03-10 Polypeptides homologues de vegf et bmp1

Publications (1)

Publication Number Publication Date
IL138488A0 true IL138488A0 (en) 2001-10-31

Family

ID=26716852

Family Applications (5)

Application Number Title Priority Date Filing Date
IL13848899A IL138488A0 (en) 1998-03-17 1999-03-10 Polypeptides homologous to vegf and bmp1
IL138488A IL138488A (en) 1998-03-17 2000-09-14 VEGF-E polypeptides, nucleic acids encoding them, the process for their preparation, preparations, vectors, storage cells and methods using such polypeptides
IL189573A IL189573A0 (en) 1998-03-17 2008-02-18 A chimeric polypeptide comprising a vascular endothelial cell growth factor-e (vegf-e) polypeptide fused to a heterologous amino acid sequence
IL189571A IL189571A0 (en) 1998-03-17 2008-02-18 Use of a vascular endothelial cell growth factor-e (vegf-e) antagonist for the preparation of and as medicaments for inhibiting or preventing growth of cancer cells or angiogenesis
IL189572A IL189572A (en) 1998-03-17 2008-02-18 Isolated antibody that binds to the polypeptide of endothelial vascular tumor factor (E – VEGF) factor and its use in the preparation of drugs and drugs for inhibiting or preventing the growth of cancer cells or vascular culture, a method of using it and a product containing it

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL138488A IL138488A (en) 1998-03-17 2000-09-14 VEGF-E polypeptides, nucleic acids encoding them, the process for their preparation, preparations, vectors, storage cells and methods using such polypeptides
IL189573A IL189573A0 (en) 1998-03-17 2008-02-18 A chimeric polypeptide comprising a vascular endothelial cell growth factor-e (vegf-e) polypeptide fused to a heterologous amino acid sequence
IL189571A IL189571A0 (en) 1998-03-17 2008-02-18 Use of a vascular endothelial cell growth factor-e (vegf-e) antagonist for the preparation of and as medicaments for inhibiting or preventing growth of cancer cells or angiogenesis
IL189572A IL189572A (en) 1998-03-17 2008-02-18 Isolated antibody that binds to the polypeptide of endothelial vascular tumor factor (E – VEGF) factor and its use in the preparation of drugs and drugs for inhibiting or preventing the growth of cancer cells or vascular culture, a method of using it and a product containing it

Country Status (14)

Country Link
US (11) US6455283B1 (fr)
EP (2) EP2016951B1 (fr)
JP (3) JP4532733B2 (fr)
AT (1) ATE405651T1 (fr)
AU (1) AU758353B2 (fr)
CA (1) CA2322792C (fr)
CY (2) CY1108500T1 (fr)
DE (1) DE69939374D1 (fr)
DK (2) DK1064382T3 (fr)
ES (2) ES2313778T3 (fr)
HK (1) HK1125853A1 (fr)
IL (5) IL138488A0 (fr)
PT (1) PT2016951E (fr)
WO (1) WO1999047677A2 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053760A2 (fr) * 1999-03-12 2000-09-14 Genentech, Inc. Technique permettant de prevenir la mort des neurones retiniens et traitement des maladies oculaires
US6803194B1 (en) 1998-02-13 2004-10-12 Hk Pharmaceuticals, Inc. Use of ribozymes for functionating genes
WO1999044533A1 (fr) * 1998-03-06 1999-09-10 Crosscart, Inc. Xenogreffes de tissus mous
AU758353B2 (en) * 1998-03-17 2003-03-20 Genentech Inc. Polypeptides homologous to VEGF and BMP1
EP0984063A3 (fr) * 1998-08-31 2000-08-16 Eli Lilly And Company Gene et proteine apparentee au vegf
ES2432053T3 (es) * 1998-12-07 2013-11-29 Zymogenetics, Inc. Homólogo del factor del crecimiento ZVEGF3
US6663870B2 (en) * 1998-12-07 2003-12-16 Zymogenetics, Inc. Methods for promoting growth of bone using zvegf3
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
DE69936733T2 (de) * 1998-12-22 2008-06-05 Janssen Pharmaceutica N.V. Vaskulärer endothelialer wachstumsfaktor x
EP1710299A3 (fr) * 1998-12-30 2007-01-10 Millennium Pharmaceuticals, Inc. Proteines secretées et polynucleotides codant pour ces proteines
JP2004516227A (ja) * 1999-03-08 2004-06-03 ジェネンテック・インコーポレーテッド 免疫関連疾患を治療するための組成物と方法
AU4008500A (en) * 1999-04-06 2000-10-23 Eli Lilly And Company Platelet-derived growth factor related gene and protein
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
AU7868000A (en) * 1999-10-07 2001-05-10 Curagen Corporation Growth factor polypeptides and nucleic acids encoding same
AU8031700A (en) * 1999-10-21 2001-04-30 Zymogenetics Inc. Method of treating fibrosis
US6893637B1 (en) * 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
WO2001032197A2 (fr) * 1999-11-02 2001-05-10 Eli Lilly And Company Methodes d'utilisation de lp8, une proteine liee au pdgf, afin de traiter les troubles musculosquelettiques
CN101053573A (zh) * 2000-01-19 2007-10-17 帕卡什·S·吉尔 针对反义vegf寡核苷酸的方法和组合物
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
CA2403829A1 (fr) * 2000-03-28 2001-10-04 Ludwig Institute For Cancer Research Animaux transgeniques non humains exprimant un facteur de croissance c derive de plaquettes (pdgf-c) et utilisations
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US7166280B2 (en) * 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US20050277576A1 (en) * 2000-04-06 2005-12-15 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20070111935A1 (en) * 2000-04-06 2007-05-17 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
AU5523701A (en) * 2000-04-06 2001-10-23 Wayne P Franco Methods of using growth factors for treating heart disease
CA2404616C (fr) 2000-04-12 2009-08-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Utilisation de vegf et d'homologues pour traiter des troubles du neurone
AU2001265953B2 (en) * 2000-05-12 2005-09-29 D. Collen Research Foundation Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
US7175844B2 (en) * 2000-07-18 2007-02-13 Joslin Diabetes Center, Inc. Methods of modulating fibrosis
US20020091082A1 (en) * 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
WO2002033094A1 (fr) * 2000-10-19 2002-04-25 Kyowa Hakko Kogyo Co., Ltd. Anticorps inhibant l'activite vplf
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
KR20030081402A (ko) * 2001-03-09 2003-10-17 얀센 파마슈티카 엔.브이. Ｖｅｇｆ-ｘ 또는 그의 길항제에 의한 평활근 세포 증식의조절
US6913762B2 (en) * 2001-04-25 2005-07-05 Mayo Foundation For Medical Education And Research Stent having non-woven framework containing cells
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
WO2003049773A1 (fr) * 2001-12-11 2003-06-19 Fibrogen, Inc. Procede pour inhiber des processus oculaires
WO2003092665A2 (fr) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Systemes oculaires de distribution de medicament et utilisation associee
WO2003094617A2 (fr) * 2002-05-06 2003-11-20 Genentech, Inc. Utilisation de vegf pour traiter des defauts osseux
US20060122387A1 (en) * 2002-06-13 2006-06-08 Cti Europe S.R.L. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
CA2509063C (fr) * 2002-11-16 2010-11-02 Dade Behring Marburg Gmbh Scd40l et facteur de croissance placentaire (pigf) servant de combinaisons de marqueurs biochimiques pour des maladies cardiovasculaires
US20090155266A1 (en) * 2004-01-16 2009-06-18 Yale University Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
WO2005087177A2 (fr) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Anticorps chimeriques anti-vegf-d et anticorps humanises anti-vegf-d et leurs procedes d'utilisation
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
ES2351804T3 (es) 2004-05-27 2011-02-10 Vib, Vzw Tratamiento de esclerosis lateral amiotrófica.
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
ES2565481T3 (es) * 2005-03-24 2016-04-05 Thrombogenics N.V. Anticuerpo anti-PlGF novedoso
ES2363758T3 (es) * 2005-08-15 2011-08-16 Vegenics Pty Ltd Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
PL2548578T3 (pl) 2006-05-17 2014-12-31 The Ludwig Institute For Cancer Res Kierowanie regulacją transporterów kwasów tłuszczowych przez VEGF-B, w celu modulowania ludzkich chorób
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EA018848B1 (ru) * 2010-10-20 2013-11-29 Вадим Юльевич ШАНИН Иммунологически активное вещество, способ его получения, биозонд на его основе и способ диагностики состояния здоровья с применением биозонда, фармацевтическая композиция и способ лечения с использованием фармацевтической композиции
WO2013079713A1 (fr) 2011-12-01 2013-06-06 Thrombogenics Nv Amélioration du résultat de la trabéculectomie
WO2013160359A1 (fr) 2012-04-24 2013-10-31 Thrombogenics N.V. Anticorps anti-pdgf-c
NZ701949A (en) * 2012-05-18 2016-07-29 Otago Innovation Ltd Combination treatments and compositions for wound healing
EP2968391A1 (fr) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Molécules polynucléotidiques à longue durée de vie
CN105713095B (zh) * 2016-03-14 2021-05-07 南京安吉生物科技有限公司 一种多功能融合多肽及其制备方法和应用
KR101943081B1 (ko) 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2035733A (en) * 1935-06-10 1936-03-31 Marathon Electric Mfg Fan motor mounting
US2813673A (en) * 1953-07-09 1957-11-19 Gilbert Co A C Tiltable oscillating fan
US2765977A (en) * 1954-10-13 1956-10-09 Morrison Hackley Electric ventilating fans
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4568243A (en) * 1981-10-08 1986-02-04 Barry Wright Corporation Vibration isolating seal for mounting fans and blowers
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4703152A (en) * 1985-12-11 1987-10-27 Holmes Products Corp. Tiltable and adjustably oscillatable portable electric heater/fan
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5106748A (en) 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
US4877864A (en) 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
US5631142A (en) 1986-07-01 1997-05-20 Genetics Institute, Inc. Compositions comprising bone morphogenetic protein-2 (BMP-2)
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5543394A (en) 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US4850804A (en) * 1986-07-07 1989-07-25 Tatung Company Of America, Inc. Portable electric fan having a universally adjustable mounting
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
EP0266032A1 (fr) 1986-08-29 1988-05-04 Beecham Group Plc Enzyme fibrinolytique modifiée
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
EP0308936B1 (fr) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Hétéroconjugués d'anticorps pour tuer des cellules infectées par VIH
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
CA2020729A1 (fr) 1989-07-19 1991-01-20 Michael C. Kiefer Proteine morphogenetique des os
EP0416578B1 (fr) 1989-09-06 1996-07-31 Takeda Chemical Industries, Ltd. Protéine, ADN et leur utilisation
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
USD325435S (en) * 1990-09-24 1992-04-14 Vornado Air Circulation Systems, Inc. Fan support base
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1992020373A1 (fr) 1991-05-14 1992-11-26 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
US5382569A (en) 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
CA2108770C (fr) 1991-06-25 2007-04-03 John M. Wozney Compositions de bmp-9
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
US5296769A (en) * 1992-01-24 1994-03-22 Electrolux Corporation Air guide assembly for an electric motor and methods of making
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
DE69233803D1 (de) * 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
RO118524B1 (ro) 1992-11-13 2003-06-30 Idec Pharmaceuticals Corp San Metoda pentru tratarea unei tulburari legata de celulele b
US5310313A (en) * 1992-11-23 1994-05-10 Chen C H Swinging type of electric fan
ATE186219T1 (de) 1993-03-24 1999-11-15 Berlex Biosciences Kombination von antihormonale und bindende moleküle zur krebsbehandlung
EP0694080B1 (fr) 1993-04-05 2005-12-07 University of Utah Research Foundation Diagnostic et traitement du retrecissement aortique supravalvulaire
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
KR100329409B1 (ko) 1993-08-26 2002-03-20 브루스 엠. 에이센, 토마스 제이 데스로저 인간 골 형태발생 단백질을 사용한 신경 재생법
US5773223A (en) 1993-09-02 1998-06-30 Chiron Corporation Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof
PT733109E (pt) 1993-12-07 2006-07-31 Genetics Inst Llc Proteinas morfogeneticas dos 0ss0s pmo-12 e pmo-13 e as suas composicoes para inducao de tendao
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
ES2276393T3 (es) 1994-04-25 2007-06-16 Genentech, Inc. Cardiotrofina y sus usos.
US5454419A (en) 1994-09-19 1995-10-03 Polybore, Inc. Method for lining a casing
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5518370A (en) * 1995-04-03 1996-05-21 Duracraft Corporation Portable electric fan with swivel mount
SG68529A1 (en) 1995-05-25 1999-11-16 Univ Singapore The use of des-aspartate-angiotensin i (agr-val-tyr-ile-his-pro-phe-his-leu) as an anti-cardiac hypertrophic agent
DK0886679T3 (da) * 1996-02-28 2007-09-24 Bayer Healthcare Ag Parakoppevira indeholdende fremmed DNA, fremstilling heraf og deres anvendelse i vacciner
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
DE69740038D1 (fr) * 1996-07-12 2010-12-16 Genentech Inc
WO1998006724A1 (fr) 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Agonistes du recepteur du glutamate metabotropique
EP0956339B1 (fr) * 1996-08-23 2005-10-12 Ludwig Institute For Cancer Research Facteur d recombinant de croissance des cellules endotheliales vasculaires (vegf-d)
NZ500077A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized antibodies to vascular endothelial growth factor (VEGF) and methods for their preparation.
USD398983S (en) * 1997-08-08 1998-09-29 Vornado Air Circulation Systems, Inc. Fan
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
AU2562199A (en) 1998-01-27 1999-08-09 Eli Lilly And Company Vegf related gene and protein
DK1490386T3 (da) 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
AU758353B2 (en) * 1998-03-17 2003-03-20 Genentech Inc. Polypeptides homologous to VEGF and BMP1
CA2334075A1 (fr) 1998-07-15 2000-01-27 Human Genome Sciences, Inc. Proteine morphogenetique osseuse
EP1123408A1 (fr) 1998-09-30 2001-08-16 Ludwig Institute For Cancer Research Facteur de croissance c derive des plaquettes, adn le codant et ses utilisations
JP2003524383A (ja) 1998-10-28 2003-08-19 インサイト・ファーマスーティカルズ・インコーポレイテッド 成長因子関連分子
US20030027998A1 (en) * 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
MXPA01005169A (es) 1998-12-01 2002-07-02 Genentech Inc Promocion o inhibicion deangiogenesis y cardiovascularizacion.
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
ES2432053T3 (es) 1998-12-07 2013-11-29 Zymogenetics, Inc. Homólogo del factor del crecimiento ZVEGF3
DE69936733T2 (de) 1998-12-22 2008-06-05 Janssen Pharmaceutica N.V. Vaskulärer endothelialer wachstumsfaktor x
EP1710299A3 (fr) 1998-12-30 2007-01-10 Millennium Pharmaceuticals, Inc. Proteines secretées et polynucleotides codant pour ces proteines
US6155782A (en) * 1999-02-01 2000-12-05 Hsu; Chin-Tien Portable fan
JP2004516227A (ja) 1999-03-08 2004-06-03 ジェネンテック・インコーポレーテッド 免疫関連疾患を治療するための組成物と方法
AU4008500A (en) 1999-04-06 2000-10-23 Eli Lilly And Company Platelet-derived growth factor related gene and protein
WO2000066736A1 (fr) 1999-05-03 2000-11-09 Zymogenetics, Inc. Homologue du facteur de croissance zvegf4
CA2360344C (fr) * 1999-12-06 2003-02-18 The Holmes Group, Inc. Element chauffant pivotant
US20030181377A1 (en) * 2002-02-12 2003-09-25 Vanderbilt University Inhibition of VEGF receptor signaling reverses tumor resistance to radiotherapy
BR0201397B1 (pt) * 2002-04-19 2011-10-18 arranjo de montagem para um ventilador de refrigerador.
US6830433B2 (en) * 2002-08-05 2004-12-14 Kaz, Inc. Tower fan
US7059826B2 (en) * 2003-07-25 2006-06-13 Lasko Holdings, Inc. Multi-directional air circulating fan
US20050128698A1 (en) * 2003-12-10 2005-06-16 Huang Cheng Y. Cooling fan
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
US7088913B1 (en) * 2004-06-28 2006-08-08 Jcs/Thg, Llc Baseboard/upright heater assembly
CN2835669Y (zh) * 2005-09-16 2006-11-08 霍树添 立柱式电风扇的送风机构

Also Published As

Publication number Publication date
IL138488A (en) 2008-06-05
US7494977B2 (en) 2009-02-24
US20100331251A1 (en) 2010-12-30
WO1999047677A3 (fr) 1999-11-11
JP2010001292A (ja) 2010-01-07
JP2013224300A (ja) 2013-10-31
IL189572A (en) 2013-01-31
CA2322792A1 (fr) 1999-09-23
CY1108500T1 (el) 2014-04-09
US6620784B1 (en) 2003-09-16
IL189573A0 (en) 2009-02-11
IL189571A0 (en) 2009-02-11
CA2322792C (fr) 2010-09-14
JP4532733B2 (ja) 2010-08-25
EP1064382B1 (fr) 2008-08-20
CY1113126T1 (el) 2016-04-13
AU758353B2 (en) 2003-03-20
US7371377B2 (en) 2008-05-13
US20070031929A1 (en) 2007-02-08
US20040219640A1 (en) 2004-11-04
US20080095773A1 (en) 2008-04-24
AU3075099A (en) 1999-10-11
IL189572A0 (en) 2009-02-11
JP5473441B2 (ja) 2014-04-16
US20110319327A1 (en) 2011-12-29
US20090012003A1 (en) 2009-01-08
DE69939374D1 (de) 2008-10-02
DK2016951T3 (da) 2012-09-24
US20030113870A1 (en) 2003-06-19
HK1125853A1 (en) 2009-08-21
ES2389387T3 (es) 2012-10-25
ES2313778T3 (es) 2009-03-01
JP5931801B2 (ja) 2016-06-08
PT2016951E (pt) 2012-09-27
EP2016951B1 (fr) 2012-06-27
US6455283B1 (en) 2002-09-24
AU758353C (en) 1999-10-11
US7575879B2 (en) 2009-08-18
WO1999047677A2 (fr) 1999-09-23
JP2004515201A (ja) 2004-05-27
ATE405651T1 (de) 2008-09-15
US20090264370A9 (en) 2009-10-22
US20040235740A1 (en) 2004-11-25
EP1064382A2 (fr) 2001-01-03
EP2016951A1 (fr) 2009-01-21
US20080299119A1 (en) 2008-12-04
DK1064382T3 (da) 2008-12-08

Similar Documents

Publication Publication Date Title
HK1125853A1 (en) Polypeptides homologous to vegf and bmp1
EP0484401A4 (en) Production of vascular endothelial cell growth factor
AU582225B2 (en) Xenogeneic collagen/mineral preparations in bone repair
AU7783587A (en) Novel osteoinductive compositions
AU5649586A (en) Partially purified bone-inducing factor
EP1666499A3 (fr) Nouveaux inhibiteurs de l'activité du facteur de croissance endothelial vasculaire (VEGF), leurs utilisations et leurs procédés de production
DE60007079D1 (de) Methoden und zusammensetzungen zur heilung und reparatur von gelenkknorpeln
NZ335109A (en) Stable analogs of keratinocyte growth factor (KRF) useful for preventing alopecia, treating gastro-duodenal ulcers, bowel disease, liver function or general induction epithelial cell proliferation
ATE117558T1 (de) Verbesserte resorbierbare knochenwachse.
DE69939330D1 (de) Wachstumsfaktor-homologe zvegf-3
ATE339878T1 (de) Myc-bindende zinkfinger-proteine, ihre herstellung und ihre verwendung
WO2001005810A3 (fr) DERIVES PEPTIDIQUES CYCLIQUES SERVANT D'INHIBITEURS DE L'INTEGRINE αVβ¿6?
ATE123056T1 (de) Ancrod-proteine, ihre herstellung und verwendung.
AU6860294A (en) New chondrocyte proteins
ES2186501A1 (es) Factor de crecimiento fibroblastico basico con un dominio de union especifico a colegeno.
ATE130872T1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
RU2000113937A (ru) НОВЫЙ ФАКТОР РОСТА/ДИФФЕРЕНЦИАЦИИ TGF-β-СЕМЕЙСТВА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
FF Patent granted